天津医药

• 论著 • 上一篇    下一篇

EPHX1基因多态性与华法林稳定剂量关系的研究

黄盛文1,向道康2,陈保林1,黄凌1,安邦权1,李贵芳1   

  1. 1. 贵州省人民医院
    2. 贵州省人民医院心外科
  • 收稿日期:2011-04-01 修回日期:2011-06-01 出版日期:2011-10-15 发布日期:2011-10-15
  • 通讯作者: 黄盛文

Study on the association between EPHX1 polymorphism and warfarin maintenance dose

  • Received:2011-04-01 Revised:2011-06-01 Published:2011-10-15 Online:2011-10-15
  • Contact: Sheng-Wen HUANG

PDF (PC)

2167

摘要： 目的：探讨环氧化物水解酶基因（epoxide hydrolase 1, EPHX1）rs4653436（G＞A）多态性位点与个体间华法林稳定剂量差异的关系。方法：采用聚合酶链反应/变性高效液相色谱技术，检测217例已获得华法林稳定剂量患者的rs4653436（G＞A）位点基因型；比较不同基因型患者华法林稳定剂量的差异。结果：217例患者中，基因型GG、GA和AA分别有141例、72例和4例，各占64.4%、32.9%和1.8%，G和A等位基因的频率分别为81.6%和18.4%。在3种基因型中，GG、GA和AA患者的华法林稳定剂量分别为2.84±1.19 mg/d、2.91±1.09 mg/d和2.66±1.29 mg/d，3组之间差异无统计学意义（P=0.856）。结论：EPHX1 rs4653436（G＞A）基因多态性可能不是影响华法林个体间用量差异的遗传因素。

关键词: 环氧化物水解酶基因, 基因分型, 华法林, 个体化用药

Abstract: Objective: To investigate the association between EPHX1 rs4653436（G＞A） polymorphism and inter-individual warfarin maintenance dose. Methods: The genotypes of 217 patients with stable warfarin dose were determined by using of a PCR/DHPLC genotyping assay. The warfarin maintenance doses were compared among patients with different genotypes. Results: In the total of 217 patients, the numbers of GG, GA and AA genotype were 141, 72 and 4, with the frequencies of 64.4%, 32.9% and 1.8%, respectively. The frequencies of G and A allele were 81.6% and 18.4%, respectively. The mean stable doses of patients with GG, GA and AA genotype were 2.84±1.19 mg/d, 2.91±1.09 mg/d and 2.66±1.29 mg/d respectively. There was no significant difference (P=0.483) in mean stable dose among the three genotype groups (P=0.856). Conclusion: EPHX1 rs4653436（G＞A）polymorphism may be not a genetic factor that influence the inter-individual warfarin maintenance dose.

Key words: EPHX1, genotyping, warfarin, personalized medicine